Tratar a Enxaqueca em Portugal: (Quando) Haverá uma Mudança de Paradigma? Um Apelo à Ação

GBD 2021 Nervous System Disorders Collaborators. Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol. 2024;23(March, 14):344–81.

Steiner TJ, Stovner LJ, Vos T, Jensen R, Katsarava Z. Migraine is first cause of disability in under 50s: will health politicians now take notice? Journal of Headache and Pain. 2018.

IHME U of W. Institute for Health Metrics and Evaluation (IHME). GBD Compare Data Visualization. [Internet]. Seattle, WA. 2020 [cited 2024 Mar 20]. Available from: http://vizhub.healthdata.org/gbd-compare(link is external).

MiGRA PORTUGAL. “Acesso aos Cuidados de Saúde na Enxaqueca e Cefaleias.” Lisboa; 2023.

Gil-Gouveia R, Pereira L, Machado S, Parreira E. Organização de Serviços de Apoio Clínico para Doentes com Cefaleias em Portugal. Sinapse. 2021;21(2):112–20.

IQVIA. IQVIA Hospital Vision Jan 2024. Portugal; 2024.

Vandervorst F, Van Deun L, Van Dycke A, Paemeleire K, Reuter U, Schoenen J, et al. CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. J Headache Pain. 2021;22(1):1–11.

Messina R, Huessler EM, Puledda F, Haghdoost F, Lebedeva ER, Diener HC. Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis. Cephalalgia. 2023;43(3).

Gil-Gouveia R, Dolezil D, Paemeleire K, et al. Sustained benefit of monthly erenumab versus daily oral preventives in episodic migraine patients from the APPRAISE study. In: 8th Congress of the European Academy of Neurology. Vienna; 2022. p. S11.001.

Reuter U, Ehrlich M, Gendolla A, Heinze A, Klatt J, Wen S, et al. Erenumab versus topiramate for the prevention of migraine – a randomised, double-blind, active-controlled phase 4 trial. Cephalalgia. 2022;42(2).

Lazaro-Hernandez C, Caronna E, Rosell-Mirmi J, Gallardo VJ, Alpuente A, Torres-Ferrus M, et al. Early and annual projected savings from anti-CGRP monoclonal antibodies in migraine prevention: a cost-benefit analysis in the working-age population. J Headache Pain [Internet]. 2024;25(1):1–9. Available from: https://doi.org/10.1186/s10194-024-01727-0

WHO. Quality of Health Care. 2024.

Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update. J Headache Pain [Internet]. 2022;23(1):1–19. Available from: https://doi.org/10.1186/s10194-022-01431-x

Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update. Headache. 2024;(February):1–9.